No Data
No Data
Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
H.C. Wainwright Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Diamedica Therapeutics (DMAC)